BRPI0418552A - compostos de alvejamento de piperidinila que seletivamente ligam-se à integrinas - Google Patents

compostos de alvejamento de piperidinila que seletivamente ligam-se à integrinas

Info

Publication number
BRPI0418552A
BRPI0418552A BRPI0418552-8A BRPI0418552A BRPI0418552A BR PI0418552 A BRPI0418552 A BR PI0418552A BR PI0418552 A BRPI0418552 A BR PI0418552A BR PI0418552 A BRPI0418552 A BR PI0418552A
Authority
BR
Brazil
Prior art keywords
integrins
piperidinyl
selectively bind
targeting compounds
formula
Prior art date
Application number
BRPI0418552-8A
Other languages
English (en)
Inventor
Bart De Corte
William A Kinney
Bruce E Maryanoff
Shyamali Ghosh
Liu Li
Livia Brunner
Robert A Galemmo Jr
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0418552A publication Critical patent/BRPI0418552A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"COMPOSTO DE ALVEJAMENTO DE PIPERIDINILA QUE SELETIVAMENTE LIGAM-SE à INTEGRINAS". A presente invenção refere-se à síntese e aplicação biológica de porção de afinidade de antagonistas de integrina de ácido carboxílico de piperidinoíla da Fórmula (I) e Fórmula (II). Estas porções de afinidade podem ser empregadas com lipossomas ou agentes de imageamento para alvejar células que expressam os receptores de integrina <244> v~ <244> 3~ <244> v~ <244> 5~, ou <244> v~ <244> 6~.
BRPI0418552-8A 2004-02-18 2004-03-29 compostos de alvejamento de piperidinila que seletivamente ligam-se à integrinas BRPI0418552A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/782,060 US20040224986A1 (en) 2002-08-16 2004-02-18 Piperidinyl targeting compounds that selectively bind integrins
PCT/US2004/009465 WO2005082889A1 (en) 2004-02-18 2004-03-29 Piperidinyl targeting compounds that selectively bind integrins

Publications (1)

Publication Number Publication Date
BRPI0418552A true BRPI0418552A (pt) 2007-05-22

Family

ID=34911385

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418552-8A BRPI0418552A (pt) 2004-02-18 2004-03-29 compostos de alvejamento de piperidinila que seletivamente ligam-se à integrinas

Country Status (19)

Country Link
US (3) US20040224986A1 (pt)
EP (1) EP1718635A1 (pt)
JP (1) JP2007523907A (pt)
KR (1) KR20070010125A (pt)
CN (1) CN101023072A (pt)
AU (1) AU2004316476A1 (pt)
BR (1) BRPI0418552A (pt)
CA (1) CA2556768A1 (pt)
EA (1) EA200601517A1 (pt)
EC (1) ECSP066778A (pt)
HR (1) HRP20060298A2 (pt)
IL (1) IL177502A0 (pt)
IS (1) IS8532A (pt)
ME (1) MEP48908A (pt)
MX (1) MXPA06009503A (pt)
NO (1) NO20064212L (pt)
RS (1) RS20060470A (pt)
WO (1) WO2005082889A1 (pt)
ZA (1) ZA200607756B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
US8926945B2 (en) 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
US8680278B2 (en) * 2007-10-30 2014-03-25 Janssen Pharmaceutica Nv Enantioselective process for preparing a substituted alkanoic acid
EP3673922A1 (en) * 2008-03-14 2020-07-01 VisEn Medical, Inc. Integrin targeting agents and methods of using same
JP5502076B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド 新規化合物
WO2009147188A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Benzpyrazol derivatives as inhibitors of pi3 kinases
WO2009147190A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited Novel compounds
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
RS53830B1 (sr) 2009-04-30 2015-06-30 Glaxo Group Limited Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
DK3929196T3 (da) 2013-09-24 2023-09-25 Fujifilm Corp Farmaceutisk sammensætning af en nitrogenholdig forbindelse eller salt deraf, eller metalkompleks deraf
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417018D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604681D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
IL309955A (en) 2018-04-27 2024-03-01 Arrowhead Pharmaceuticals Inc Integrin-targeting ligands and their uses
IL305752A (en) * 2021-03-10 2023-11-01 Dice Molecules Sv Inc INTEGRIN INHIBITORS OF ALPHA V BETA 6 AND ALPHA V BETA 1 AND THEIR USES
WO2025067433A1 (zh) * 2023-09-28 2025-04-03 云合智药(苏州)生物科技有限公司 靶向整合素的化合物及其在RNAi剂中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (pt) * 1977-06-03 1981-03-07 Pfizer
EP1306095A3 (en) * 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5902795A (en) * 1992-06-16 1999-05-11 Trustees Of Tufts College Oligosaccharides reactive with hyaluronan-binding protein and their methods of use
US5340798A (en) * 1992-10-14 1994-08-23 Merck & Co., Inc. Fibrinogen receptor antagonists
US5753659A (en) * 1993-03-29 1998-05-19 Zeneca Limited Heterocyclic compouds
CA2216943C (en) 1995-04-19 2003-06-17 Boston Scientific Limited Drug release coated stent
DE19613933A1 (de) 1996-04-06 1997-10-09 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US5919792A (en) * 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
CA2272090A1 (en) 1996-12-09 1998-06-18 Matthew J. Fisher Integrin antagonists
PE122699A1 (es) 1997-09-19 2000-02-12 Smithkline Beecham Corp Antagonistas de receptores de vitronectina
US6211191B1 (en) * 1997-12-17 2001-04-03 Merck & Co., Inc. Integrin receptor antagonists
SK9192000A3 (en) 1997-12-17 2001-03-12 Merck & Co Inc Integrin receptor antagonists
ES2241313T3 (es) 1998-03-31 2005-10-16 Bristol-Myers Squibb Pharma Company Compuestos farmaceuticos para la formacion de imagenes de trastornos angiogenicos.
UA71586C2 (en) 1998-12-04 2004-12-15 Smithkline Beecham Corp A vitronectin receptor antagonist
ATE362772T1 (de) 1998-12-18 2007-06-15 Bristol Myers Squibb Pharma Co Vitronektin rezeptor antagonist arzneimitteln oder diagnostika
NZ511677A (en) 1998-12-18 2003-10-31 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals
EP1140864A2 (en) 1998-12-18 2001-10-10 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
AU750584B2 (en) 1999-02-17 2002-07-25 Merck & Co., Inc. Dibenzo-azepine derivatives as alphav integrin receptor antagonists
EP1179541B1 (en) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
DE60035779T2 (de) 1999-06-02 2008-04-30 Merck & Co., Inc. Alpha v integrin-rezeptor antagonisten
CA2352957A1 (en) 1999-09-29 2001-04-05 Ortho-Mcneil Pharmaceutical, Inc. Isonipecotamides for the treatment of integrin-mediated disorders
AU5752601A (en) * 2000-05-04 2001-11-12 Avi Biopharma Inc Splice-region antisense composition and method
US6776796B2 (en) * 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
JP2004511434A (ja) 2000-06-15 2004-04-15 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
US20040009465A1 (en) 2002-07-12 2004-01-15 Voraphat Luckanatinvong Shelf life indicator components for fresh cut fruits and vegetables responding to carbondioxide
EP1539739B1 (en) * 2002-08-16 2010-11-24 Janssen Pharmaceutica NV Piperidinyl compounds that selectively bind integrins
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins

Also Published As

Publication number Publication date
US20110092528A1 (en) 2011-04-21
ZA200607756B (en) 2008-06-25
US20040224986A1 (en) 2004-11-11
WO2005082889A1 (en) 2005-09-09
IS8532A (is) 2006-09-15
US7879881B2 (en) 2011-02-01
AU2004316476A1 (en) 2005-09-09
IL177502A0 (en) 2006-12-10
EP1718635A1 (en) 2006-11-08
ECSP066778A (es) 2006-11-16
KR20070010125A (ko) 2007-01-22
HRP20060298A2 (hr) 2007-03-31
EA200601517A1 (ru) 2007-06-29
US20080058359A1 (en) 2008-03-06
JP2007523907A (ja) 2007-08-23
NO20064212L (no) 2006-11-15
CN101023072A (zh) 2007-08-22
MEP48908A (bs) 2011-02-10
US8110683B2 (en) 2012-02-07
CA2556768A1 (en) 2005-09-09
MXPA06009503A (es) 2007-04-19
RS20060470A (sr) 2008-11-28

Similar Documents

Publication Publication Date Title
EP1766017A4 (en) TUMOR-SPECIFIC ANTIBODY
DK1272507T3 (da) Integrinbindende peptidderivater
UY26057A1 (es) Amidas de aminoacidos modificadas, medicamentos que contienen estos compuestos y procedimiento para su preparacion
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
EP2109625A4 (en) USE OF ANTIBODY CONJUGATES
EP2170388A4 (en) ANTIBODY FORMULATIONS
MA29014B1 (fr) Formulations d&#39;anticorps
FR2892923B1 (fr) Utilisatiion des derives de l&#39;acide para-coumarique ou para- hydroxycinnamique dans des compositions cosmetiques ou dermatologiques.
ATE484505T1 (de) 5-sulfanylmethylä1,2,4ütriazolä1,5-aüpyrimidin- - olderivate als cxcr2-antagonisten
ZA200705043B (en) Contrast agents to target extracellular matrix
EP2007899A4 (en) ANGIOPOIETIN-LIKE PROTEIN 4-FACED ANTIBODIES AND THEIR USE
EP2322562A4 (en) MONOCLONAL ANTIBODY AND IMMUNASSAY WITH IT
BR0210720A (pt) Composto e uso do mesmo
UY28773A1 (es) Nuevas amidas de ácidos carboxílicos, su preparación y su uso como medicamentos.
WO2006090389A3 (en) Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
ECSP066778A (es) Compuestos direccionales de piperidinilo que se unen selectivamente a integrinas
EP1542721A4 (en) MODIFIED &#34;S&#34; ANTIBODIES
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
BR0315032A (pt) Composição destinada a aplicação à pele e aos tegumentos
MX2010000997A (es) Combinaciones farmaceuticas que comprenden un inhibidor de tirosina cinasa y un anticuerpo contra integrina alfa 1 beta 5 (cd49b).
EP1758605A4 (en) PROUROGUANYLIN AS THERAPEUTIC AND DIAGNOSTIC AGENTS
SG152257A1 (en) Topical preparation containing ambroxol
ATE352567T1 (de) Herstellung von agonisten und antagonisten von cholecystokinin und ihre therapeutische und diagnostische verwendung
BR9916807A (pt) Antagonistas de 5ht1 para terapia antidepressiva
WO2008039843A3 (en) Novel peptides that promote lipid efflux

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 3A, 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.